Nuvation Bio Inc (NUVB NYSE) stock market data APIs
$4.8067
-0.43(-8.9%)
as of May 5, 2026
Try our APIs with
free plan!
Nuvation Bio Inc Financial Data Overview
Price chart is built with
Anychart
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Prev. Close
4.8067
Open
4.3794
High
4.8378
Low
4.111
52 wk Range
1.57-9.75
Market Cap
1 682 M
Shares Outstanding
347 M
Revenue
143 M
EPS
-0.11
Beta
1.516
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Nuvation Bio Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Nuvation Bio Inc data using free add-ons & libraries
Get Nuvation Bio Inc Fundamental Data
Nuvation Bio Inc Fundamental data includes:
- Net Revenue: 143 M
- EBITDA: -148 214 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2026-03-02
- EPS/Forecast: -0.09
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Nuvation Bio Inc News
New
Nuvation Bio's Supplemental NDA With Updated Data For IBTROZI Wins FDA Acceptance
(RTTNews) - Wednesday, Nuvation Bio Inc. (NUVB) announced that the U.S. Food and Drug Administration has accepted a supplemental New Drug Application with updated data for IBTROZI for the treatment of...
Nuvation Bio expects gross-to-net to stabilize around 30% as IBTROZI shifts to >50% TKI-naive starts
Earnings Call Insights: Nuvation Bio (NUVB) Q1 2026 MANAGEMENT VIEW * Dr. David Hung said the launch is being driven by steady demand and an improving mix toward earlier-line use: “We successful...
Nuvation Bio Inc. Q1 2026 Earnings Call Summary
Nuvation Bio Inc. Q1 2026 Earnings Call Summary - Moby Strategic Execution and Market Dynamics Performance in Q1 was characterized by a significant shift in patient mix, with TKI-naive (first-line) ...
Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
Achieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI® (taletrectinib); majority of the approximately 200 patients started on IBTROZI in the first quarter of 2026 were TKI-...
Get Nuvation Bio Inc fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
